clinical trial · NCT07255638
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Indolent Systemic MastocytosisAvapritinib
brief summary
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.
started
Dec 9, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 20, 2026
official title
A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol